The study authors said the method also has the advantages of having a quick turnaround and a relatively low cost.
Investigators say they have uncovered a potential new biomarker that could help physicians better assess the risk of relapse in patients treated for acute lymphoblastic leukemia (ALL). This new method relies on the analysis of cell-free DNA (cfDNA) to detect the presence of ALL in patients, which investigators say could help flag patients even if blasts are not readily apparent. The report was published in Frontiers in Oncology.
The study authors noted that ALL is the most common pediatric malignancy, but in a majority of cases (90%) is curable. Those who face the steepest odds are patients who experience relapse following treatment and those whose disease spreads to the central nervous system (CNS).
“The prevalence of CNS disease in ALL is high enough that every ALL patient receives prophylactic treatment involving multiple doses of intrathecal chemotherapy, which can have adverse and long-term side effects in pediatric patients,” the investigators noted.
Thus, they said, there is a need for more precise tools to risk stratify patients.
The current best practice of measuring response to treatment is looking at the presence or absence of minimal residual disease (MRD) by analyzing patient samples using flow cytometry or microscopy.
“Developing more sensitive assays that depend on the molecular detection of leukemic blasts via next-generation sequencing has proven difficult since ALL has one of the lowest mutational burdens of any cancer,” they wrote.
In their new paper, the investigators proposed looking at cfDNA, which are DNA fragments released by cancer cells and detectable in patient biofluids.
“Tumor-specific cfDNA increases as tumors grow,” they noted. “The half-life of cfDNA is only 15 to 120 minutes, making it a valuable and proven biomarker for detecting cancer development in healthy individuals and monitoring tumor response to treatment in cancer patients.”
The investigators decided to develop a workflow using Nanopore MinION sequencing of PCR-amplified B-cell–specific rearrangement of the IGH locus in the cfDNA of patients with B-cell ALL. They then tested the method on samples from 5 pediatric patients.
The results were compelling. The investigators said their method allowed them to assess patient response throughout the treatment process at a level superior to that of MRD.
“cfDNA was detected in patient biofluids with clinical diagnoses of MRD and CNS disease, and leukemic clones could be detected even when diagnostic cell-count thresholds for MRD were not met,” they wrote.
Moreover, they said their method has several other advantages, including a quick turnaround time and low cost. They added that the method could also be useful on a larger scale.
“The workflow could be scaled up for quickly and efficiently assessing the dynamics of B-ALL clones in response to treatment in large patient datasets, particularly in consortia studying B-ALL,” they wrote.
The authors conceded that their study was based on a small sample size of just 5 patients. However, they said the results suggest the workflow could be a useful tool. They said a future study with 20 to 30 patients “will be sufficient for proof of concept to show that cfDNA assays may be useful in detecting the presence of ALL in patients when blasts are not in the biofluid sample.”
Reference
Sampathi S, Chernyavskaya Y, Haney MG, et al. Nanopore sequencing of clonal IGH rearrangements in cell-free DNA as a biomarker for acute lymphoblastic leukemia. Front Oncol. 2022;12:958673. doi:10.3389/fonc.2022.958673
Emily Goldberg Shares Insights as a Genetic Counselor for Breast Cancer Risk Screening
October 30th 2023On this episode of Managed Care Cast, Emily Goldberg, MS, CGC, a genetic counselor at JScreen, breaks down how genetic screening for breast cancer works and why it is so important to increase awareness and education around these screening tools available to patients who may be at risk for cancer.
Listen
Machine Learning Model Predicts Hepatocellular Carcinoma Risk in Patients With MASLD
March 22nd 2024Machine learning models have potential for early identification of patients with metabolic dysfunction-associated steatotic liver disease (MASLD) who are at risk of hepatocellular carcinoma.
Read More
Examining Telehealth Uptake to Increase Equitable Care Access
January 26th 2023To mark the publication of The American Journal of Managed Care®’s 12th annual health IT issue, on this episode of Managed Care Cast, we speak with Christopher M. Whaley, PhD, health care economist at the RAND Corporation, who focuses on health economics issues, including the influence of the COVID-19 pandemic on health care delivery.
Listen
CMS is highly likely to negotiate the price of the obesity medication semaglutide in the coming years; many health care providers are trying to determine whether their cyberattack insurance will help cover their losses after the Change Healthcare hack; the US life expectancy increased for the first time in 2 years.
Read More
A global AIDS program that was in limbo for months got temporary relief after congressional negotiators agreed to a 1-year renewal in the next government funding package; the outcome of the November presidential election could determine the state of fetal tissue research in the US; federal officials and industry executives failed to make improvements that stop hacking attacks.
Read More